JUBLPHARMA — Jubilant Pharmova Cashflow Statement
0.000.00%
- IN₹173.32bn
- IN₹187.97bn
- IN₹72.35bn
- 93
- 25
- 85
- 79
Annual cashflow statement for Jubilant Pharmova, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 8,711 | 6,304 | 278 | 1,705 | 9,806 |
Depreciation | |||||
Non-Cash Items | 6,058 | 1,978 | 2,288 | 3,735 | -1,505 |
Discontinued Operations | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2,212 | -3,724 | -1,500 | 454 | -1,266 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 17,073 | 8,375 | 6,607 | 9,713 | 10,721 |
Capital Expenditures | -5,275 | -6,000 | -8,144 | -8,977 | -11,156 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -2,115 | 2,196 | 2,700 | 2,898 | 16,033 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -7,390 | -3,804 | -5,444 | -6,079 | 4,877 |
Financing Cash Flow Items | -2,922 | -1,349 | -2,342 | -2,437 | -2,356 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -17,094 | -326 | -1,567 | -4,325 | -14,527 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -7,289 | 4,819 | 301 | -575 | 1,319 |